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Inactivating mutations in chromodomain helicase DNA binding protein
7 (CHD7) cause CHARGE syndrome, a severe multiorgan system dis-
order of which Isolated gonadotropin-releasing hormone (GnRH)
deficiency (IGD) is a minor feature. Recent reports have described
predominantly missense CHD7 alleles in IGD patients, but it is unclear
if these alleles are relevant to causality or overall genetic burden of
Kallmann syndrome (KS) and normosmic form of IGD. To address this
question, we sequenced CHD7 in 783 well-phenotyped IGD patients
lacking full CHARGE features; we identified nonsynonymous rare se-
quence variants in 5.2% of the IGD cohort (73% missense and 27%
splice variants). Functional analyses in zebrafish using a surrogate oto-
lith assay of a representative set of these CHD7 alleles showed that
rare sequence variants observed in controls showed no altered func-
tion. In contrast, 75% of the IGD-associated alleles were deleterious
and resulted in both KS and normosmic IGD. In two families, patho-
genic mutations in CHD7 coexisted with mutations in other known IGD
genes. Taken together, our data suggest that rare deleterious CHD7
alleles contribute to the mutational burden of patients with both KS
and normosmic forms of IGD in the absence of full CHARGE syndrome.
These findings (i) implicate a unique role or preferential sensitivity for
CHD7 in the ontogeny of GnRH neurons, (ii) reiterate the emerging
genetic complexity of this family of IGD disorders, and (iii) demonstrate
how the coordinated use of well-phenotyped cohorts, families, and
functional studies can inform genetic architecture and provide insights
into the developmental biology of cellular systems.
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Inactivating mutations in the gene encoding chromodomainhelicase DNA binding protein 7 (CHD7, MIM 608892) cause
a severe developmental disorder that affects multiple organ systems
and is referred to as CHARGE syndrome (Coloboma, Heart de-
fects, choanal Atresia, Retardation of growth and development,
Gonadal defects, and Ear/hearing abnormalities, MIM 214800)
(1–3). More than 90% of the reported mutations causing this
syndrome are de novo severe truncating lesions that are equally
distributed across CHD7’s 37 exons and various functional do-
mains (3–6). The “gonadal defect” in CHARGE patients is in fact
hypogonadotropic hypogonadism, which is typically responsive to
exogenous gonadotropin-releasing hormone (GnRH) administra-
tion: that is, they represent isolated GnRH deficiency (IGD) (7–11).
IGD is an inherited reproductive disorder caused by defects in
the secretion of GnRH and its action on the anterior pituitary
gonadotrope (12). Around 60% of IGD patients also manifest
a variety of nonreproductive defects, principally anosmia, which
defines Kallmann syndrome (KS), whereas the remainder exhibit
a pure nonsyndromic neuroendocrine phenotype, referred to
as normosmic IGD (nIGD) (12, 13). In KS, a shared migratory
defect of GnRH and olfactory axons produces IGD and anosmia,
respectively, whereas other defects result from perturbation of
other developmental pathways and processes (14). In contrast,
the biological basis of nIGD cases resides in the failure of one or
more hypothalamic neuroendocrine systems (12).
Several recent reports have suggested that rare sequence
variants (RSVs) in CHD7 occur in ∼6% of IGD patients either
with (9, 15) or without (8) any features of CHARGE syndrome.
Although the initial report implicated CHD7 in both KS and
nIGD (8), two subsequent studies detected putative pathogenic
CHD7 RSVs in KS patients only (9, 16). However, the possible
effects of these IGD-associated CHD7 variants on protein func-
tion have not been investigated to date (8, 9, 15, 16). Therefore,
we sought to: (i) determine the frequency spectrum, phenotypes,
genotypes, and mode of inheritance of CHD7 RSVs in a large,
well-characterized cohort of IGD; (ii) characterize functionally
a representative spectrum of these IGD- and CHARGE-associated
RSVs; and (iii) consider whether differential activity of the
protein, or loss thereof, contributes to KS/nIGD/CHARGE or
other specific endophenotypes.
Significance
Inactivating mutations in the chromodomain helicase DNA
binding protein 7 (CHD7) gene causes a severe developmental
disorder known as CHARGE syndrome. Recently, several mis-
sense mutations in CHD7 have been reported in isolated
gonadotropin-releasing hormone (GnRH) -deficiency (IGD) patients
who lack full CHARGE features. However, the precise functional
consequence of these IGD-associated missense mutations on the
activity of CHD7 protein is not known. This study confirms the
predominance of missense CHD7 alleles in 5% of IGD patients
and provides, to our knowledge, first experimental evidence
that functionally compromised CHD7 missense alleles contribute
to the pathogenesis of both the anosmic and normosmic forms
of IGD. These results imply a preferential sensitivity for CHD7
dysfunction in the developmental ontogeny as well as neuro-
endocrine regulation of GnRH neurons in humans.
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Results
RSVs in CHD7 Are Common in IGD Patients.All 37 exons and intron–
exon junctions of CHD7 were sequenced in 783 well-phenotyped
patients with IGD. Following further detailed phenotypic review
of patients with demonstrable mutations, four from the original
cohort with an initial diagnosis of IGD were reclassified as
CHARGE syndrome. Overall, we identified CHD7 RSVs in 41
IGD patients (5.2%) lacking full CHARGE features (Fig. 1 and
Table S1), a number consistent with previous reports (8, 16).
Only 9 of 41 of these CHD7+ IGD patients showed evidence of
minor CHARGE features (Table S2). In keeping with a recent
report (16), a striking feature of this cohort was that, in contrast
to the truncating CHD7 mutations observed typically in patients
with CHARGE, patients with IGD harbored predominantly
missense variants (n = 30 of 41; 73%), with a smaller number of
patients harboring predicted splice-variants (n = 11 of 41; 27%).
All patients harboring CHD7 RSVs were heterozygotes except
for two individuals who each displayed two RSVs; however, no
parental DNAs were available to determine their phase. All four
patients who fulfilled the Verloes criteria for full CHARGE
syndrome (17) harbored a single heterozygous CHD7 RSV (one
nonsense, one frameshift, and two missense variants) (Table S3).
All RSVs identified in IGD patients and in full CHARGE
patients are shown in Fig. 1.
IGD and CHARGE Patients Are Enriched for Functionally Deleterious
RSVs. Computational analysis of the functional impact of the
identified CHD7 variants was performed using multiple software
programs (SI Materials and Methods). Splice sequence analysis
using three prediction programs predicted that only one putative
splice variant would affect splice efficiency/utilization in two or
more programs (Table S4). Modeling of the missense alleles
produced significant discordance in the various predictions algo-
rithms (Table S5). Given the known ambiguity of these prediction
programs (18), we assessed the functionality of the IGD-associated
RSVs using an in vivo zebrafish model. We selected a represen-
tative spectrum of 20 different nonsynonymous missense RSVs
for extensive functional analyses based on their population fre-
quency (Table S6) and associated human phenotypes (Tables
S1–S3). The RSVs chosen for these analyses fell into three
groups: (i) Group A (control alleles; n = 3): RSVs seen in IGD
subjects but also seen with ≥0.5% minor allele frequency (MAF)
in the National Heart, Lung, and Blood Institute (NHLBI)
exome database (p.S103T, p.M340V, p.L2984F) (18); (ii) Group
B (alleles associated with IGD without full CHARGE; n = 12):
RSVs (MAF < 0.5%) consisting of six alleles found in IGD
subjects lacking any CHARGE features (p.Y1616C, p.G1982E,
p. I2064V, p.I2232V, p.T2532M, p.Q2621E), three from IGD
patients without any CHARGE features but who carried addi-
tional heterozygous mutations in other genes previously iden-
tified to be associated with IGD (p.G1845R, p.E1897K,
p.A2789V), and three from patients with IGD who had minor
CHARGE features (p.P940L, p.F1362L, p.R2065G); and (iii)
Group C (alleles associated with full CHARGE; n = 5): RSVs
(MAF < 0.5%) from CHARGE syndrome patients identified ei-
ther in this study (p.V1021G, p.A1289V) or reported previously in
the CHD7 database (p.I1028V, p.D1596G, p.D1812H) (www.chd7.
org/molgenis.do) (6).
To test the consequences of these missense mutations on
protein function, we injected a previously reported splice-
blocking morpholino (MO) against chd7 (chd7-MO) (19) into
one- to four-cell–stage zebrafish embryos. Consistent with pre-
vious reports (19), injected embryos displayed abnormal otoliths
at 3 days postfertilization (dpf), one of the many CHARGE
phenotypes. We grouped the resulting embryos into four objec-
tive classes: normal, small (posterior otolith same size or smaller
to anterior otolith), fused/three, or absent otoliths. Each of the
20 CHD7 missense RSVs was tested for either its relative ability
to rescue the morphant phenotype or its ability to phenocopy
MO-induced otolith defects when overexpressed (under a domi-
nant paradigm). For in vivo rescue, the chd7-MO (6 ng) and each
mutant CHD7 missense mRNA (5 pg) were injected and each
experiment was scored blind to injection mixture and performed
in triplicate. All morphant phenotypes could be rescued by coin-
jection of WT human CHD7 mRNA (Fig. 2A, Inset F), whereas
WT overexpression in the absence of MO produced no appre-
ciable phenotypes (Fig. 2C). Because the mutant CHD7 S103T
control allele was able to rescue the morphant phenoptype in-
distinguishable from WT human CHD7 mRNA, all of the rescue
experiments for mutant CHD7 alleles were statistically compared
against the S103T allele (Fig. 2B). Results for all mutant alleles on
both assays are presented except for the Q2621E allele for which
the rescue experiment failed and is not shown.
All three CHD7 RSVs from group A (control alleles) were
able to rescue morphant phenotypes in a manner indistinguish-
able from WT human CHD7 and did not show any dominant
activity upon overexpression (Fig. 2 B and C). These data sup-
port the population frequency-derived prediction that group A
alleles, with a MAF > 0.5%, are likely benign and bolstered
confidence on the specificity of the assay. Among the 12 CHD7
alleles found in IGD patients without full CHARGE (group B),
five alleles (p.F1362L, p.G1845R, G1982E, p.I2064V, and
p.I2232V) showed partial loss of function (LOF) in that the
frequency of abnormal otolith phenotypes was significantly bet-
ter than MO alone yet significantly worse than controls (P < 0.05
for each comparison, scored blind and in triplicate), indicating
they were likely hypomorphic alleles (Fig. 2B). Four alleles
(p.P940L, p.E1897K, p.T2532M, and p.Q2621E) showed a dom-
inant effect in the overexpression assay (i.e., each induced the
absence of otoliths in a small but significant number of embryos)
(P < 0.05) (Fig. 2C). Three alleles (p.Y1616C, p.R2065G, and
p.A2789V) tested benign in both assays (Fig. 2 B and C). Thus,
75% (9 of 12) of IGD-associated (group B) missense RSVs
tested in the functional assays were either hypomorphic or dom-
inant, indicating an enrichment of functionally deleterious var-
iants in this group compared with the controls in group A. Of the
five alleles associated with the full CHARGE syndrome in group
C, one was null (p.I1028V), two were hypomorphic (p.D1596G
and p.D1812H), and two (p. A1289V and p.V1021G) were
dominant (Fig. 2 B and C).
Finally, integration of 3D structural modeling of CHD7
using an automated homology model by SWISS-MODEL
Fig. 1. CHD7 protein domains and positions of RSVs
identified in CHARGE syndrome and IGD. Both
CHARGE- and IGD-associated variants in CHD7 were
equally dispersed across its 37 exons without muta-
tional hot spots. Most mutations identified in CHARGE
syndrome are nonsense or frameshift, whereas the
vast majority of RSVs found in IGD are missense var-
iants. RSVs identified in family members with delayed
puberty, anosmia, and unaffected carriers were depicted
along with RSVs seen in probands. BRK, Brahma and
Kismet domain; CD, chromodomain; DEXHc, DEAD-like
helicase superfamily including an ATP-binding domain;
NLS, nuclear localization signal.
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(swissmodel.expasy.org/) (20) or the FoldX protein design al-
gorithm (21) predicted that four variants (p.P940L, p.V1021G,
p.A1289V, p.G1982E) disrupted the 3D protein structure of
CHD7 (Fig. 3) and all of these four variants were also determined
to be deleterious RSVs from the zebrafish experiments. These
variants were located in the chromo, SNF2, or helicase domains,
all known to play important roles in chromatin remodeling (22).
Deleterious CHD7 Missense Variants Cause both KS and nIGD Without
Full CHARGE. A total of 10 IGD subjects with both phenotypic
forms (n = 6, KS; n = 4, nIGD) harbored pathogenic CHD7
missense mutations (Table 1). Only two of these patients had
additional features of CHARGE but none fulfilled the Verloes
criteria for full typical/atypical CHARGE syndrome (Table 2).
However, when taking into consideration the presence of any
CHARGE feature in patients harboring these deleterious CHD7
variants (Tables 1 and 2), patients with minor/full CHARGE
were associated significantly with the KS phenotype (P = 0.0165),
suggesting that the KS form of IGD is the primary allelic variant
of CHARGE syndrome rather than its normosmic counterpart.
However, the occurrence of deleterious CHD7 RSVs in the
normosmic patients suggests that CHD7’s effect may not be
limited to GnRH migration alone. In addition, one nIGD subject
(Pedigree #35) (Fig. 1 and Table 1) had an adult-onset pre-
sentation of IGD, further confirming a neuroendocrine role for
CHD7 in the pathogenesis of IGD. The clinical characteristics of
patients with benign CHD7 alleles are also shown in Table S7.
The clinical characteristics of patients with CHD7 alleles that
were not tested in zebrafish assay are shown in Table S8.
Segregation Analysis Suggests Complex Inheritance Patterns. For
functionally deleterious CHD7 variants in the IGD pedigrees
where inheritance information was available, none were de novo
nor was there any apparent parent of origin bias (Fig. 4 and
Table 1). These findings contrast previously reported CHARGE-
causing variants that are typically de novo and show a preference
for paternal inheritance (23). Segregation analysis also showed
that the discovered CHD7 alleles are not sufficient to explain the
observed phenotypes (Fig. 4). In two families, the pathogenic
CHD7 variants were found in IGD patients who also carried a
known pathogenic mutation in a second IGD gene (FGFR1 in
pedigree #24 and GNRHR in pedigree #25), raising the possi-
bility that some CHD7 alleles might interact genetically with other
IGD mutations and thus contribute to the reported oligogenic
nature of IGD (24) (Fig. 4 and Table 1). However, interpreting
such genetic architecture based on a small number of candidate
epistatic events must be done with caution because segregation
analysis of the CHD7 alleles was incomplete in these oligogenic
pedigrees (Fig. 4). However, in both of these oligogenic pedigrees,
the presence of another IGD-associated genetic variant did not
Fig. 2. Functional assessment of CHD7 RSVs in zebrafish assay. (A) The otic vesicle of control-MO–injected zebrafish contains two otoliths (Inset A). Larva
treated with an MO against chd7 show normal (Inset B), three/fused (Inset C), or small (Inset D) or absent (Inset E) otoliths, whereas coinjection of WT
human CHD7 rescues the morphant phenotype showing normal two otoliths (Inset F). (B) In vivo rescue assay: Coinjection of human CHD7mRNA encoding
mutant S103T allele along with chd7 MO results in significant rescue of morphant phenotype indistinguishable from WT rescue. Coinjection of chd7 MO
with human CHD7 mRNAs encoding the two other control alleles (p.M340V, p.L2984F) from group A (see main text) shows rescue similar to S103T allele.
Five IGD-associated CHD7 alleles (p.F1362L, p.G1845R, G1982E, p.I2064V, and p.I2232V) from group B (see main text) were partial LOF alleles (hypo-
morphs). Of the CHARGE-associated CHD7 alleles (group C, see main text), one was complete LOF (null) (p.I1028V) and two were hypomorphic (p.D1596G
and p.D1812H). The remaining CHD7 alleles were benign on the rescue assay. (C ) Overexpression of human mutant CHD7 mRNAs in zebrafish: over-
expression of the human WT CHD7 mRNA did not induce any appreciable phenotypes. Four IGD-associated CHD7 alleles (p.P940L, p.E1897K, p.T2532M,
and p.Q2621E) from group B (see main text) and two CHARGE-associated CHD7 alleles (p. A1289V and p.V1021G) from group C (see main text) showed
a dominant effect in the overexpression assay. The remaining CHD7 alleles were benign on the overexpression assay. ***P < 0.0005, **P < 0.005, *P < 0.05;
NS, not significant.
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appear to heighten the occurrence of any CHARGE-related
phenotypes; that is, these patients exhibited IGD only. This ob-
servation suggests that these other IGD-causing genes probably
lack direct functional synergy with CHD7 in the developmental
pathways involved in the non-GnRH organ systems involved in
CHARGE syndrome.
Discussion
In this study, a large, well-phenotyped cohort of IGD patients,
with both KS and nIGD that were assembled without preselection
for or against known mutations in known IGD genes, were ana-
lyzed to assess the contribution of CHD7 to IGD. In contrast to
truncating CHD7 mutations occurring in typical CHARGE syn-
drome, ∼5.2% of IGD patients without full CHARGE features
harbored heterozygous, nonsynonymous missense or splice-
altering variants in CHD7. The observed prevalence and the
predominantly missense nature of the CHD7 variants is in accor-
dance with recent reports (8, 16). However, to our knowledge for
the first time, the functional impact of a representative subset of
the missense variants in CHD7 was assessed in a zebrafish assay
and compared with functional effects of low-frequency missense
RSVs represented in the public Exome Sequencing Project (ESP)
database. Whereas all variants from the ESP database tested
benign, ∼75% of the tested IGD-associated CHD7 RSVs were
pathogenic, acting either as clear hypomorphs that were unable to
rescue the CHD7-MO phenotype or as dominant alleles when
overexpressed. On phenotypic analysis, most IGD-patients with
deleterious missense CHD7 alleles did not fulfill full CHARGE
criteria, thus providing functional molecular validation that the
nonsyndromic form of IGD is indeed an allelic variant of
CHARGE syndrome. Segregation analysis of deleterious CHD7
variants shows incomplete penetrance and variable expressivity,
suggesting that these deleterious variants contribute to the IGD
phenotype but by themselves may be insufficient to cause it.
KS and nIGD represent the two distinct phenotypic forms of
IGD. The KS phenotype results from the neurodevelopmental
failure of GnRH neuronal migration during development and
nIGD results from the neuroendocrine failure of GnRH secretion/
action within the hypothalamus (12, 13). Whereas most genes
exclusively cause either the KS or nIGD forms of the disease,
a subset of genes (e.g., FGF8/FGFR1, PROK2/PROKR2) are as-
sociated with both KS and nIGD, indicating either (i) two po-
tentially different pathophysiologic sites of actions on the ontogeny
of GnRH neurons or (ii) the potential for dissociated effects on
the ontogeny of GnRH neurons and olfactory axons, respectively
(12, 13). Although the initial report by Kim et al. (8) implicated
CHD7 in both KS and nIGD, subsequent investigators have failed
to identify any predicted pathogenic CHD7 RSVs in nIGD (9, 16).
However, some nIGD subjects did harbor rare CHD7 alleles but
these were deemed to be benign based on prediction programs,
which are recognized to be prone to ambiguity (16). The present
study was able to address these issues by performing functional
studies and by examining the phenotypes of patients with patho-
genic CHD7 alleles, this study provides key insights into the role of
CHD7 in GnRH neuronal ontogeny. Functionally deleterious
CHD7 mutations were found in both KS and nIGD subjects, from
which it can be inferred that CHD7 likely has both distinct de-
velopmental as well as neuroendocrine roles. Moreover, four
subjects with pathogenic CHD7 alleles also had micropenis or
cryptorchidism, implying an embryonic defect in GnRH de-
velopment and secretion. These results also indicate that future
genetic evaluations of all nonsyndromic KS and nIGD should be
screened for CHD7 for sequence variants.
To date, only a few cases of parent-to-child transmission have
been reported in CHARGE pedigrees with CHD7 mutation (23,
25). In addition, over 80% of CHARGE-causing CHD7 muta-
tions are null alleles (5, 6). In our IGD patients, however, not
only were CHD7 variants inherited (where possible to assess),
but most IGD-associated CHD7 variants were either hypomorphs
Fig. 3. Structural modeling of the CHD7 chromo- and helicase domains (amino
acids 799–1511) (A) and SANT domain (amino acids 1964–2115) (B) showing
four variants (p.P940L, p.V1021G, p.A1289V, and p.G1982E) that were pre-
dicted to be detrimental to protein stability by FoldX algorithm (asterisk).
Table 1. Clinical characteristics of IGD patients without full CHARGE harboring pathogenic CHD7 mutations by zebrafish model
Pedigree
No. Sex Origin
De
novo Diagnosis Olfaction
Nucleotide
change
Amino acid
change
Exon/
Intron
Mutations in
other genes
11* M Caucasian NA KS Self-reported
anosmia
2819C > T P940L 10 None
12 M Caucasian NA nIGD Self-reported
normal
2819C > T P940L 10 None
18* M Caucasian No KS UPSIT hyposmia 4084T > C F1362L 19 None
24 F Caucasian No KS UPSIT anosmia 5533G > A G1845R 26 FGFR1: 710G >
A (G237D)
25 M Asian NA nIGD Self-reported
normal
5689G > A E1897K 29 GNRHR: 836G >
A (C279Y)
homozygote
28 M Caucasian NA KS Self-reported
anosmia
5945G > A G1982E 30 None
32 M African American NA KS UPSIT hyposmia 6190A > G I2064V 31 None
35 M Asian NA nIGD, adult
onset
UPSIT normal 6694A > G I2232V 31 None
38 F African American NA nIGD Self-reported
normal
7595C > T T2532M 34 None
44 M Caucasian NA KS Self-reported
anosmia
8405G >
A/7861C > G
G2802E/
Q2621E
38/36 None
F, female; M, male; NA, not assessed; UPSIT, University of Pennsylvania Smell Identification Test.
*Probands with additional CHARGE features but not fulfilling Verloes CHARGE syndrome criteria.
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or had a modest dominant effect. Thus, it appears that it is the
nature and severity of these variants, rather than their location
within the CHD7 gene/protein that is critical for its selective per-
turbation on developing GnRH neurons producing IGD rather
than their multiorgan involvement in CHARGE.
The present study has some limitations. The phenotypic details
of additional CHARGE features in IGD patients, as well as phe-
notypes of parents, were partly ascertained by retrospective review
of medical records, physician referral letters, and questionnaire
data. Thus, it is possible that a prospective evaluation might un-
cover additional phenotypic features of CHARGE in these IGD
patients. However, because the majority of our patients have had
detailed physician reviews either via in-house or through referrals
from multiple specialists, major CHARGE features are unlikely to
have been missed. Typical of most sequencing studies, deep-
intronic and regulatory-regions, deletions, and rearrangements
were not evaluated. However, in previous studies of CHD7
mutations, no such deletions have been found (6, 26). While IGD
subjects underwent Sanger sequencing, control CHD7 alleles were
obtained from whole-exome seqencing data from the NHLBI ESP
Exome Variant Server and, hence, potentially could be subject to
platform-specific biases in variant ascertainment. However, re-
assuringly, limited validation of ESP singleton variants has been
reported to be reliable (27) and hence biases, if any, are unlikely
to be significant. Given the complexity of design and conduct of
CHD7 functional assays, only a subset of alleles were examined.
However, multiple alleles tested consistently as hypomorphs in the
rescue experiments, validating the observed findings. Similarly,
some alleles displayed reproducible altered dominant phenotype
upon overexpression whereas WT allele overexpression did not
produce any altered phenotype. Moreover, all alleles predicted as
destabilizing on automated homology modeling were found to be
deleterious in zebrafish, further strengthening the observations.
Two alternative splice products of the CHD7 gene are known
(28, 29) but the effect the RSVs identified in this study on these
splice products were not examined in the present study. Finally,
functional assessment of CHD7 alleles was ascertained using a
surrogate otolith phenotype in zebrafish rather than GnRH or
olfactory neuronal phenotypes. However, this assay is an out-
standing proxy for CHD7 function (19) and, hence, the functional
deficits observed are unlikely to represent false-positive results. In
contrast, there is a possibility that the alleles that tested benign in
the otolith assays may actually be detrimental to protein function
below the dynamic range of the assay, representing false-negative
observations. In addition, four patients with documented hy-
pomorphic/dominant alleles in this study also displayed hearing
loss, thus confirming the biological relevance of the examined
zebrafish phenotype (Tables 1 and 2 and Table S3).
The question of where CHD7 fits into the developmental biology
of the GnRH neurons remains a mystery. Mice with completeChd7
deficiency mirror the observed human phenotypes (delayed pu-
berty, genital hypoplasia, hypogonadotropism) and display neuro-
developmental defects, including reduced GnRH neurons in the
hypothalamus and reduced expression of FGFR1 in the olfactory
placode (30, 31). Recent work also suggests that CHD7 regulates
genes involved in neural crest guidance (32), and there is increasing
evidence that KS may also result from impaired neural crest
guidance (33). Taken together, these observations suggest that
CHD7 plays an important neurodevelopmental role in the for-
mation of the hypothalamic-pituitary unit (31). That rare path-
ogenic CHD7 variants are associated with nIGD suggests that in
addition to its neurodevelopmental role, CHD7 may well also
influence subsequent neuroendocrine development pathways of
GnRH neurons. The striking predominance of missense CHD7
variants in IGD implies that this gene and its associated biological
pathways are especially critical for the ontogeny of GnRH neu-
rons. Hence, working out the function of CHD7 via comparison of
missense vs. truncating mutations might offer a route to unraveling
its unique biological role in this complex system.
Table 2. Additional CHARGE features present in IGD patients with CHD7 RSVs that were pathogenic in zebrafish model
Pedigree no. Diagnosis
Mutation in
CHD7 Second hits C H A RG RD G HL E CLP FA
Verloes criteria for
full CHARGE
11 KS P940L None — — — — — + + — — — No
18 KS F1362L None — — — NA + + + — — — No
A, atresia of choanae; C, coloboma; CLP, cleft lip/plate; E, external ear defect; FA, facial asymmetry; G, genital defects; H, heart defects; HL, hearing loss; RG,
retarded growth; RD, retarded development.
*Probands with additional CHARGE features but not fulfilling Verloes CHARGE syndrome criteria.
Fig. 4. Family pedigrees of probands with patho-
genic CHD7 mutations. Pedigrees #11, #12, #18, #28,
#33, #35, #38, and #44 harbored CHD7 mutations
alone, and pedigrees #24 and #25 harbored CHD7
mutations oligogenic with FGFR1 and GNRHR genes,
respectively. Among familial cases, pedigree #24
and pedigree #25 display incomplete penetrance for
CHD7 mutations and pedigree #18 displays variable
expressivity of GnRH deficiency/anosmia phenotypes
for the CHD7 mutation. Probands are identified by
arrows. “+” indicates WT allele.
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Materials and Methods
Study Subjects and Phenotypic Information. Included in this study were 783
consecutive patients with IGD (367 KS, 411 nIGD) from the Reproductive
Endocrine Unit of Massachusetts General Hospital, who underwent genetic
screening for 14 genes associated with IGD (see below). Diagnostic criteria for
IGD and CHARGE syndrome criteria are provided in SI Materials andMethods.
Phenotypic records from individual medical charts, patient questionnaires,
and referring provider’s summary were reviewed to ascertain additional
phenotypic information related to CHARGE syndrome, such as coloboma,
choanal atresia, external ear defects, cardiovascular malformations, cleft lip/
palate, and developmental delay. Study protocols were approved by the
Massachusetts General Hospital/Partners Institutional Review Board and in-
formed consent obtained from all participants.
Genetic Analyses. Genomic DNA was isolated from peripheral blood lympho-
cytes. In all IGD subjects, the 37 coding exons of CHD7 (exons 2–38) and their
intronic flanking regions were amplified by PCR and directly sequenced, as
described previously (9). The GenBank accession number NM_017780.2 was
used as reference sequence for CHD7. In addition, all coding exons and intronic
flanking regions of the GNRH1 (Gonadotropin-releasing hormone 1), GNRHR
(Gonadotropin-releasing hormone receptor), KISS1 (KiSS-1 metastasis-suppressor),
KISS1R (KISS1 receptor), PROK2 (prokineticin 2), PROKR2 (prokineticin receptor
2), TAC3 (tachykinin 3), TACR3 (tachykinin receptor 3), FGF8 (fibroblast growth
factor 8), FGFR1 (fibroblast growth factor receptor 1), KAL1 (kallmann syn-
drome 1 sequence), HS6ST1 (heparan sulfate 6-O-sulfotransferase 1), and NSMF
[NMDA receptor synaptonuclear signaling and neuronal migration factor;
previously called NELF (nasal embroyonic leutinizing hormone releasing hor-
mone factor)] genes were amplified by PCR with specific primers and directly
sequenced as described previously (24). Protein-altering variants in CHD7 with
a MAF < 0.5% in the NHLBI ESP Exome Variant Server (evs.gs.washington.edu/
EVS/) (34) and not reported to be benign polymorphisms in previously published
literature (5, 6), or in the CHD7 database (www.CHD7.org) were considered as
RSVs. In addition, splice-site altering variants in sequences within 8 bp of splice
junctions (the consensus sequences are AG and GT for the donor and acceptor
sites, respectively) with MAF < 0.5% in the NHLBI Exome Variant Server were
also considered as RSVs. For the other 13 IGD genes screened, previously pub-
lished pathogenic RSVs were included in the oligogenicity analysis.
Generation of Zebrafish chd7 Knockdown and Rescue Experiments. Zebrafish
chd7 knockdown was done using a splice-blocking MO (TTATTTTCTG-
GCACTAACCATGTCC), previously reported (19). One- to four-cell–stage
zebrafish embryos were injected with 6 ng MO or 5 pg mRNA. Injected
embryos were scored live at 3 dpf and classified according to the presence,
amount, and size of otoliths. To confirm the specificity of the MO, rescue
experiments were performed. Human full-length CHD7 cDNA was kindly
provided by Joanna Wysocka (Stanford School of Medicine, Stanford, CA)
and Peter C. Scacheri (Case Western Reserve University School of Medicine,
Cleveland, OH). Full-length WT CHD7was amplified and cloned into pCS2. To
generate CHD7 mutations, primers were designed to introduce the specific
change and the reaction was performed using QuikChange Site-Directed
Mutagenesis kit (Stratagene). CHD7 WT and mutations were confirmed
through Sanger sequencing, cloned into pCS2 vector, and transcribed in
vitro with the SP6 Message Machine kit (Ambion). Next, 10 pg of mRNA was
injected alone into zebrafish embryos. For rescue experiments, CHD7 WT
mRNA (5 pg) was coinjected with chd7-MO (6 ng).
Statistical Analysis. All zebrafish experiments were repeated at least three
times and a Pearson’s χ2 test was used to determine significance between
S103T allele rescue vs. mutant rescue and between WT vs. mutant CHD7
allele overexpression. The χ2 test was also used to compare the occurrence of
KS vs. nIGD in the presence of pathogenic CHD7 RSVs in IGD patients. A
P value less than 0.05 were considered as statistically significant.
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